Emerging Biotechnology Organization Awards $1.3 Million Study Extension to eResearchTechnology for Cardiac Safety Monitoring and
May 06 2004 - 10:05AM
PR Newswire (US)
Emerging Biotechnology Organization Awards $1.3 Million Study
Extension to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Overall Agreement Now Totals More
than $4.2 Million, and Includes Thorough ECG Study Profile
PHILADELPHIA, May 6 /PRNewswire-FirstCall/ -- eResearchTechnology,
Inc. (eRT), , a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has received an agreement for about $1.3
million in additional cardiac safety monitoring and services from
an emerging biotechnology organization for one of its drug
candidates in clinical development. The additional award brings to
more than $4.2 million the total services contracted to eRT for
this single clinical trial. The agreement covers an extension to a
significant Phase III study for which eRT was already providing
comprehensive support, including the provision, training and
ongoing assistance required for effective use of digital 12-lead
Holter equipment designed to facilitate 24-hour digital recording
of cardiac safety data that is subsequently provided to eRT for
analysis. The extension will enable collection and analysis of
additional cardiac safety data that will be critical in determining
the definitive cardiac effects of this new drug candidate. eRT will
perform digital collection, measurement, interpretation, review,
and distribution of cardiac safety data through its EXPeRT workflow
enabled data handling technology, the first solution in production
that was designed explicitly to meet emerging international
regulatory guidance and technical standards. The study extension is
targeted for completion over a 90-day period. "eRT's continuous
12-lead ECG recording platform has proven invaluable to this
sponsor's desire to further enhance the cardiac safety data being
collected and analyzed for this important compound," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "This extension further demonstrates the
importance of safety profiling in later stage development and
illustrates that eRT's scalable capacity is key to the ability to
rapidly deliver on unplanned increases in study demands." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10-K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci, eResearchTechnology, Inc.,
+1-908-203-6473; or Matt Hayden, Hayden Communications,
+1-858-456-4533, for eResearchTechnology, Inc. Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Aug 2024 to Sep 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Sep 2023 to Sep 2024